In a multicentre , randomised , phase 3 trial , we enrolled eligible patients aged 18 years or older with acromegaly who were inadequately controlled ( 5-point , 2 h mean growth hormone concentration > 25 g/L and insulin-like growth factor 1 [ IGF-1 ] concentration > 13 times the upper normal limit ) and had received 30 mg octreotide long-acting repeatable or 120 mg lanreotide ( Somatuline Autogel ; Ipsen , UK ) as monotherapy for 6 months or longer .